PDCD1 and melanoma: Peripheral blood profiling of melanoma patients who were candidates for immunotherapy showed that those with the LAG-3+immunotype had poorer outcomes after ICIs treatment compared to patients with the LAG-3− immunotype (median OS: 22.2 vs. 75.8 months, respectively; p = 0.031), regardless of other immune-biomarker status (PD-1, TMB) [38].